Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Common Stock (Tables)

Common Stock (Tables)

6 Months Ended

Jun. 30, 2012

Common Stock [Abstract]

Components of stock-based compensation expense


		For the six months ended June 30,								Period from June 28, 2006 (date of inception) to June 30,
($ in thousands)		2012				2011				2012
Employee awards		$	812			$	238			$	1,548
Non-employee awards			242				128				3,055
Non-employee warrants			164				164				489

Total stock-based compensation expense		$	1,218			$	530			$	5,092

Summary of stock option activity


		Outstanding Options												Weighted Average Remaining Contractual Life (in years)
($ in thousands except per share amounts)		Number of Shares				Weighted Average Exercise Price				Total Weighted Average Intrinsic Value				Weighted Average Remaining Contractual Life (in years)
At December 31, 2011			1,814,070			$	2.17			$	7,852				9.2
Options granted			540,000				6.98
Options exercised			—
Options cancelled			—

At June 30, 2012			2,354,070			$	3.27			$	4,182				8.9

Options vested and expected to vest			2,354,070			$	3.27			$	4,182				8.9
Options vested and exercisable			451,357			$	1.68			$	1,520				8.5